On September 29th, LIVZON GROUP stated on the interactive platform that the Phase III clinical trial for the weight loss indication of its Semaglutide injection has completed enrollment. The trial is designed as a head-to-head comparison with the original product, and the clinical follow-up is progressing smoothly. The company will continue to promote project progress with a scientifically efficient research and development strategy, and relevant research results and subsequent application plans will be disclosed in a timely manner in accordance with regulatory requirements
